Asensus Surgical Inc

Asensus Surgical — Investor Presentation (June 2023)

25 slides from Asensus Surgical's investor presentation, Jun 5, 2023

  1. Slide 1: Asensus Surgical: Changing the idea of what's possible in Surgery

    JUNE 2023 Asensus Surgical Changing the idea of what’s possible in Surgery PRESENTED BY Anthony Fernando, President & CEO shameze Rampertab, EVP & CFO AASENSUS WSSuURGICAL

  2. Slide 2: Forward Looking Statements

    Asensus Surgical Forward Looking Statements This presentation includes statements relating to the LUNA™ Surgical System next-generation program under development and an update on ‘Asensus’ strategic plan. These statements and other statements regarding our future plans and goals constitute "forward-

  3. Slide 3: Asensus Surgical vision statement

    A\SENSUS SURGICAL We believe in digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

  4. Slide 4: We are Delivering the Future of Surgery

    We are Delivering the Future of Surgery 10,000+ Procedures 100+ Surgeons 2,500+ Patient Registry -ASENSUS ii Senhance’ Global l Regulatory Wr Jy Approvals 5 wy LW, fx me = 300+ Fe > Patents* { , Utilization across multiple 90+ Accelerating procedure volumes jalt 2020 > 2021 +47% Sheela ity areas: Pu

  5. Slide 5: A Revolution in the Evolution of Surgery

    A Revolution in the Evolution of Surgery Improving Patient Outcomes that Robotics was not able to accomplish ee a io — we Digital tools increase: ae + Safety 8 § + Predictability 3S + Consistency is} =e = = e é Improved outcomes by Outcomes largely ee rere @ reciucing inveshveness tanchanged pal on

  6. Slide 6: Market Opportunity

    Market Opportunity Soft Tissue Robotic Surgery Soft Tissue Surgery Surgery Growth Segments (09 Procedure #9) to Reena) (eect Breskoun by roe Total Market 26% 38M of 2030 market peal — Lap Market ™ 19M Colorectal Robotics 8% a 1.8M of 2022 market -ASENSUS 200 coer

  7. Slide 7: Challenges in Surgery Today

    Challenges in Surgery Today Robotics Not High Cost of Improving Outcomes Current Robotics 1.9M Surgical Up to 2X Greater Complications Annually3**10 Procedural Cost? -ASENSUS Impending Surgeon Shortage ae >40% Physician Burnout?

  8. Slide 8: Our Solution: Performance-Guided Surgery

    Our Solution: Performance- Guided Surgery Real-Time Decision Support Tools and Robotic Precision That Drive Consistently Superior Outcomes 01 Robotic Manipulation Q2 intra-operative Clinical Guidance Q3 cloud integration

  9. Slide 9: Enabling Performance-Guided Surgery

    Enabling Performance-Guided Surgery The only way to improve outcomes is to combine Robotic Precision with real-time Surgical Decision Support with a solution accessible to more patients LUNA", Isu™ Enabling Surgery 4 = Empowering Surgeons Intra-operative digital toolkit for “Real- State of the art r

  10. Slide 10: LUNA System Overview

    LUNA System Overview Instinctive Collaborative Enabling Surgeon Console Robotic Arms Instruments ee ee — Boece ee eee et ee 186% §38% f 25% = 1 300% = Articulating Dexterity : tees fice ed-sideaccess TONY Rangeof Per casecost diameter for docking woticn vs. Competitive Robotic Systems vs.Senhance v5

  11. Slide 11: LUNA Video

    LUNA Video ASENSUS

  12. Slide 12: ISU — The Missing Piece in the OR

    ISU — The Missing Piece in the OR Empowering Surgeons Informing surgical decisions Digital measurements guiding surgeons and surgical maneuvers. Avoiding preventable errors Identification of critical anatomy to mitigate risk of tissue damage* improving OR efficiency Hands-free camera control enables

  13. Slide 13: ISU: Providing Intra-operative Decision Support

    ISU Providing Intra-operative Decision Support Follow Me 3D Measurement No Fly Zones Follow Me Video 3D Messurement Video. No Fly Zones Video ASENSUS

  14. Slide 14: Competitive Landscape

    Competitive Landscape compeny — AASENSUS —istuirive Medtronic i) (Paste) Technology General, GYN, General, cvu, | Seneral, SYN, Specialty ‘ Y. | URO, Pediatric, URO, Pediatric URO, Pediatr fe URO Real-Time Digital Tools AASENSUS — «snisionyearvaes onsbicasiaieintrmstion py aehmbet ronspemnatigei ne

  15. Slide 15: Performance-Guided Surgery

    Performance-Guided Surgery A Comprehensive Solution for Surgeons, Hospitals, & Patients Challenges in Robotics Not High Cost of Impending Surgeon ounEry Improving Outcomes Current Robotics Shortage ao ao + Patient & Surgeon Centric Gen 2 + Low-costarchitecture + Ergonomics workstation LUNA + ISU + D

  16. Slide 16: Value Drivers in Key Markets

    Value Drivers in Key Markets Unmatched Clinical Utility, Simplicity, and Savings in a Wide Range of Specialties oy Gynecology LPC Colorectal Addressable Market irnuel Volumes) 5 0 Procedures 2 Procedures + Compelingrelmbursement + RAShighiy procedures Market Dynamics + Exp. shortage of08.GYN physici

  17. Slide 17: Expanding Sites of care

    Expanding Sites of care LUNA Positioned to Serve Hospitals and Alternate Surgical Settings Market trends: = Surgical volume growth in US Hospital Outpatient (HOPDs) and Ambulatory Surgery Centers (ASCs) will continue to outpace growth in inpatient setting. "Service lines such as general surgery seei

  18. Slide 18: Developing Next Generation Technology

    Developing Next Generation Technology Broadening Applicability of Senhance and Developing the Next Wave of PGS Technology Final Testing Early Customer Design Builds Usability Studies Engagement & Pre- Commercial Manufacturing Ramp up Design Validation Glnical Pilot Launch Integrated Pre-Clinical Usa

  19. Slide 19: De-Risked Regulatory Pathway for LUNA

    De-Risked Regulatory Pathway for LUNA Ability to Leverage Senhance Clearances on LUNA Regulatory Strategy ~ 6 SF Se United States European Union Japan Rest of World 08 approved ce marked MDA Approved fui, Ton Others Senhance System Intelligent Surgical Unit Q - @ Q QQQQRQ QR RQQRQ_ QR RRQ QR G -ASEN

  20. Slide 20: Disruptive Economic Model

    Disruptive Economic Model LUNA and ISU Designed to Drive Adoption via High Clinical Performance and Responsible Economics LUNA Surgical System Standalone ISU * Annual Service Fee * Annual Service Fee + Annual Service Fee * Per Case Fee * Per Case Fee + Al Subscription (add on) * Specialty Instrument

  21. Slide 21: Financial Snapshot

    Financial Snapshot FY 2022 Performance * 29% Year-over-year growth in surgical procedures (>3,100 procedures globally) * Nine Senhance initiations + Revenue of $7.1 million 1Q 2023 Performance + 20% Year-over-year growth in surgical procedures (>900 in the quarter) * Revenue of $1.0 million Mar 31,

  22. Slide 22: Conclusion

    Conclusion Surgical outcomes can be improved. Asensus is the right company to advance that vision. We are delivering Performance-Guided Surgery through the combination of advanced Robotic Precision with real-time Surgical Decision Support: + LUNA: Next Generation digital surgery platform and instrum

  23. Slide 23: Surgery Reimagined

    Surgery Reimagined Performance-Guided Surgery — next level technology that completely changes the idea of what's possible,

  24. Slide 24: Asensus Surgical

    Asensus Surgical NYSE American: ASXC Inf ion for Investors Follow Us On Social Media Clinical Resources Visit our IR Website: (BB) etree comtcomanresn tae Visit our Corporate Website: ir.asensus.com/ asensus.com/ a IR Contact: Explore Senhance: ; youtube.com/tanserterix invest@asensus.com o senhance

  25. Slide 25: References

    References 1. shctncay wt oust Nemoon,Syansvon i Yenc Sabre astedverslagaozopunealngunaleriareaaiaconprenersvecostarl Suetndoie 2019023101945 2, ALGhunsim loson van cs AlshahraniEM Dunning, Oenner DB. Surgeon burnout. noacton patent safeyandrofesionl ystenntiereviw an8 mete nails An) Sire 20222280 P

Asensus Surgical — Investor Presentation (June 2023) on 6ix